The test is intended to address chronic kidney disease. Credit: Pixel-Shot/Shutterstock.com.

Digital health company Everly Health has introduced a comprehensive at-home collection kidney health test for chronic kidney disease (CKD).

The test is intended for health plans and employers to expand access to prevent, diagnose and treat CKD.

To assess kidney function through urine collection, the test combines an estimated glomerular filtration rate through blood collection, an estimation of kidney function and a urinary albumin-to-creatinine ratio.

When compared against standard collection methods, the methods utilised for this test have a correlation of more than 98.6%.

Furthermore, the test intends to reduce lifetime costs linked to CKD and diabetes by enhancing accessibility to testing and satisfying the 2024 KED HEDIS measure.

To ensure tests attain or exceed traditional laboratory tests’ accuracy, Everly Health leverages advanced technology and processes tests at Clinical Laboratory Improvement Amendments-certified and College of American Pathologists-accredited labs.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Everly Health Solutions chief commercial officer Dr Liz Kwo said: “Kidney disease affects 37 million adults in the United States but 90% are unaware they even have it, which makes it a silent killer.

“We have an opportunity to significantly change the course of chronic kidney disease in the United States by working to ensure early detection is available to people through the testing they need to protect their kidney health.”

Partnering with more than 100 enterprise clients, Everly Health is a virtual care provider that utilises advanced diagnostics and remote-based care to enhance the early detection and prevention of disease.